Humacyte Makes First Symvess Sale to US Military Treatment Facility

MT Newswires Live

2025/07/23

Humacyte (HUMA) said Wednesday that it has sold its first sale of Symvess to a US military treatment facility serving around 200,000 active-duty personnel, retirees, and their families.

The company said the sale follows Symvess's recent listing on the US Defense Logistics Agency's ECAT system, enabling its access across 35 military treatment facilities and 160 US Department of Veterans Affairs hospitals.

Symvess received US FDA approval for treating extremity vascular trauma in December.

Shares of the company were up more than 7% in recent Wednesday premarket activity.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553248059"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553248059\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553248059?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553248059","market":"sh","top_or_hot":-1,"title":"Humacyte Makes First Symvess Sale to US Military Treatment Facility","media":"MT Newswires Live","content":"<html><body><p> Humacyte (HUMA) said Wednesday that it has sold its first sale of Symvess to a US military treatment facility serving around 200,000 active-duty personnel, retirees, and their families.</p><p>The company said the sale follows Symvess's recent listing on the US Defense Logistics Agency's ECAT system, enabling its access across 35 military treatment facilities and 160 US Department of Veterans Affairs hospitals.</p><p>Symvess received US FDA approval for treating extremity vascular trauma in December.</p><p>Shares of the company were up more than 7% in recent Wednesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Humacyte Makes First Symvess Sale to US Military Treatment Facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHumacyte Makes First Symvess Sale to US Military Treatment Facility\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-07-23 20:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Humacyte (HUMA) said Wednesday that it has sold its first sale of Symvess to a US military treatment facility serving around 200,000 active-duty personnel, retirees, and their families.</p><p>The company said the sale follows Symvess's recent listing on the US Defense Logistics Agency's ECAT system, enabling its access across 35 military treatment facilities and 160 US Department of Veterans Affairs hospitals.</p><p>Symvess received US FDA approval for treating extremity vascular trauma in December.</p><p>Shares of the company were up more than 7% in recent Wednesday premarket activity.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日強勢股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2553248059","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553248059","pubTimestamp":1753275243,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Humacyte  said Wednesday that it has sold its first sale of Symvess to a US military treatment facility serving around 200,000 active-duty personnel, retirees, and their families.The company said the sale follows Symvess's recent listing on the US Defense Logistics Agency's ECAT system, enabling its access across 35 military treatment facilities and 160 US Department of Veterans Affairs hospitals.Symvess received US FDA approval for treating extremity vascular trauma in December.Shares of the company were up more than 7% in recent Wednesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","HUMA":"Humacyte, Inc.","BK4139":"生物科技"},"translate_title":"Humacyte首次向美国军事治疗机构出售Symvess","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HUMA":0.9},"content_text":"Humacyte (HUMA) said Wednesday that it has sold its first sale of Symvess to a US military treatment facility serving around 200,000 active-duty personnel, retirees, and their families.The company said the sale follows Symvess's recent listing on the US Defense Logistics Agency's ECAT system, enabling its access across 35 military treatment facilities and 160 US Department of Veterans Affairs hospitals.Symvess received US FDA approval for treating extremity vascular trauma in December.Shares of the company were up more than 7% in recent Wednesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}